Rechallenge therapy versus tyrosine kinase inhibitor (TKI ...
Abstract Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine/tipiracil (TAS-102), but these drugs have …
Zanzalintinib/Atezolizumab Improves CRC Survival, Expands TKI ...
Jun 23, 2025 · New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, marking a breakthrough in treatment options.
Lost in translation: Revisiting the use of tyrosine kinase ...
Nov 1, 2022 · Patients with advanced or metastatic colorectal cancer ( (m)CRC) have limited effective treatment options resulting in high mortality rates. A better understanding of the molecular basis of …
High-dose short-term osimertinib treatment is effective in ...
Apr 3, 2024 · Most tyrosine kinase inhibitors (TKIs) have failed in clinical trials for metastatic colorectal cancer (mCRC). To leverage the additional lower-affinity targets that most TKIs have, high-dose ...
Comparison of the efficacy and safety of regorafenib ...
May 28, 2025 · Background: Regorafenib is a novel tyrosine kinase inhibitor (TKIs) approved in third-line of treatment for patients with metastatic colorectal cancer (mCRC). Methods: We retrospectively …
Zanzalintinib Plus Atezolizumab Under Review for Metastatic ...
6 days ago · The FDA accepted the New Drug Application for zanzalintinib plus atezolizumab for the treatment of adult patients with metastatic colorectal cancer.
96P Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI ...
96P Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study J. Zhang 1 ∙ Q. Dong
Pfizer’s BRAFTOVI Regimen Improves Progression-Fre…
19 hours ago · BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in progression-free survival in BRAF V600E-mutant metastatic colorectal …
FDA approves fruquintinib in refractory metastatic colorectal ...
On November 8, 2023, the Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) for adult patients with metastatic colorectal cancer (mCRC) who received prior ...
Treatment Combinations Based in Immune Checkpoint Inhibitors ...
Dec 13, 2024 · Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using combinations based in immune checkpoint inhibitors.